Handbook
Cell Line Development Solutions for Biomanufacturing
Cell Line Development
Solutions for Biomanufacturing
Break through to next level of productivity
Introduction of ProBio Cell Line Business
2008
Launched mammalian cell line development business:
DHFR expression system
2015
Developed GS-expression-based cell line development platform
Improve the CHO cell line titer to 3g/L
2018
CHO-K1 commercial use license from ECACC
Launched GenScript ProBio’s proprietary host cell system, CHOK1-GenS
2022
Launched afucosylated host cell system, CHOK1-ADCC+
Launched pGenHT1.0-UP vector, which significantly improves cell line titer to 14g/L
Supported EMA EUA of customer's COVID-19 recombinant vaccine product
2023
Developed UproCHOTM cell culture media
ProBio has built up a high-expressing, robust and well-proven cell line technology ecosystem. It is
consisted of our proprietary CHO cell lines, CHOK1-GenS & CHOK1-ADCC+, high-expression vectors,
proprietary media systems and high-throughput and automated clone screening system.
To date, we have constructed more than 280 stable cell lines for IND filing using our cell line platform
and process.
18+ 280+ 40+ 3+
Years of experience
in CLD
Cell line projects for
Projects in clinical phase
Projects marketed
IND filing
CHO cells originated
from ECACC and
further developed by
GenScript ProBio:
CHOK1-GenS
UproCHOTM
High-expression
High-throughput &
automated
screening platform
vectors with transcrip-
tion-enhancer element:
pGenHT 1.0-UP
CHOK1-ADCC+
proprietary media
systems developed
for ProBio host cell
pGenHT 1.0-DGV
ProBio’s cell line technology ecosystem
Statistics by Dec. 2025
1
ProCLD Cell Line Development
Superior Productivity
Industry-leading Timeline
mAb titer: average 7.5 g/L, up to 15 g/L
bsAb titer: average 7.0 g/L, up to 10 g/L
Recombinant protein titer: average 5.8
g/L, up to 14.5 g/L
10 weeks: gene synthesis → Top 6 PCB
clones
14 weeks: gene synthesis → Top 1 clone
Tool Boxes for Complex Molecules
Bispecifics: Optimize plasmids ratio / culture duration / cell culture media, to improve titer
and quality, and reduce mismatches
Proteins: Tool boxes in clone screening to adjust glycotype and PTMs
ProBio delivers cell lines with superior productivity
Average titer
Titer Distribution of Top 12 Clones
20
15
10
8
7.53
6.97
5.8
6
10
5
4
2
0
0
mAb
BsAb
Protein
A
B
C
D
E
F
G
H
I
J
K
L
* The titers before process development
Statistics by Oct. 2025
ProBio has vast experiences in cell line development
of complex molecules
2
Cell Line Development for Afucosylated Antibodies
Antibody-dependent cellular cytotoxicity (ADCC), is a mechanism of cell-mediated immune
defense whereby an effector cell of the immune system actively lyses a target cell. It is important
in the efficacy of cancer antibodies, but with many approved cancer antibodies there is less ADCC
than could be desired due to nonspecific IgG competing with the drugs for binding to FcγIIIa
(CD16a) on natural killer cells (NK cells). Afucosylated antibodies overcome this problem through
improved FcγIIIa binding.
ProBio has developed ADCC-enhanced host cell line (CHOK1-ADCC+), which can produce
afucosylated antibodies with enhanced ADCC activity.
Proprietary ADCC-enhanced CHO
cell line with no IP issue
Fast Sample Preparation / Cell Line
Development for Different Applications
In-house developed FUT8 knockout
CHO cell line
Gene synthesis to purified afucosylated
antibodies in 5 weeks
Free to operate
Gene synthesis to mix pools in 12 weeks
Gene synthesis to top 6 clones in 14 weeks
5 Analytical Methods Available for ADCC Effect Evaluation
For glycan profiling: LC-MS & HPLC
For ADCC potency evaluation: affinity measurement to Fcγ Receptor (CD16a),
reporter gene assay, PBMC-based assay
CHOK1-ADCC+ Case Study
CHOK1-ADCC cell line shows great performance
in stability
CHOK1-ADCC shows similar performance in productivity
as compared to CHOK1-GenS (top 1 clone)
3.0
2.5
2.0
1.5
3.5
3.0
2.5
2.0
1.5
P0
P20
P0
P20
CHOK1- CHOK1-
ADCC+ GenS
Top 1
clone
(g/L)
(g/L)
1.0
P0
2.8
3.2
1.0
0.5
0.0
0.5
0.0
P20
2.7
2.8
Clone 6
Clone 39
Clone 48
CHOK1-ADCC+
CHOK1-GenS
The antibody was successfully afucosylated by using CHOK1-ADCC+
No differences in glycoforms were observed between P0 and P20 samples
3
ProBio Cell Line Development Services
We provide 4 stable-expression-based services to meet the different needs in discovery and preclinical
development stage.
ProGram
PreCLD
ProCLD
ProCLD plus
Service
content
Fast sample
preparation
Cell pool
development
Cell line
development
Cell line development
clone evaluation
Timeline
5 weeks
7 weeks
10 weeks
6 PCBs
14 weeks
Deliverables
Target protein, ROA
4 cell pools
Top 1 clone
Application
scenarios
Late discovery stage
Late discovery stage
Preclinical CMC stage
IND
Preclinical CMC stage
IND
Determine CMC candidate
Developability assessment
Proceed to a stable cell line
Determine CMC candidate
Developability assessment
Applications
ProBio Cell Line Platform License
In addition to cell line development services, we also offer the option of cell line platform license to
pharma & biotech customers for regulatory filing and biomanufacturing of human and animal drugs.
The features of our cell line platform license model are summarized as below:
Lum-sum payment
No clinical & product launch milestone payment
Incentives for GMP manufacturing in ProBio
Platform License Package
CHOK1-GenS /CHOK1-ADCC+ cell line
Host system
Proprietary pGenHT 1.0-DGV vector
Adaptation report
cGMP cell banking report
cGMP cell bank testing report
Vector synthesis report
Full Traceability Documentation
Detailed Protocols and Guidance
Vector map and key element description
Cell line development & cell culture protocol
Clone strategy
4
ProBio Inc.
Building 9, 311 Pennington Rocky Hill Rd,
Pennington, NJ